Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Compared to Basal Insulin Start on Metabolic Targets in Patients Living With Type 2 Diabetes and Chronic Kidney Disease (Impact GLP-1 CKD)

NCT06236672 is registered in ClinicalTrials.gov with LMC Diabetes & Endocrinology Ltd. as lead sponsor.

NCT NCT06236672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06236672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Compared to Basal Insulin Start on Metabolic Targets in Patients Living With Type 2 Diabetes and Chronic Kidney Disease (Impact GLP-1 CKD)
Lead sponsor
LMC Diabetes & Endocrinology Ltd.
Phase
Observational
Overall status
Completed
Start date
February 15, 2023
Completion date
November 29, 2023
Enrollment
348 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases, type 2 diabetes